Skip to main content

Complement Inhibitors for C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis: A Systematic Review and Bayesian Network Meta-Analysis

In brief

Pegcetacoplan was linked to 69% lower proteinuria at six months

In a review of four trials involving 265 people with C3 glomerulopathy or primary immune-complex kidney disease, pegcetacoplan reduced proteinuria by 69% versus placebo; iptacopan reduced it by 38%. Kidney-function changes were modest, and indirect comparisons cannot establish that one drug is superior. Short follow-up also leaves long-term kidney benefits and safety uncertain.

Journal
Clinical journal of the American Society of Nephrology : CJASN (Q1)
Published
18 November 2026
Study design
Systematic review / meta-analysis of RCTs
Evidence level
Level 1, High (CEBM 1a)
Authors
Priyanka Khandelwal, Anu Kaskinen, Arenn Jauhal, Christopher J Patriquin, Christoph Licht, Cal H Robinson
PMID
43050283
DOI
10.2215/CJN.0000001254

Why clinicians should know about it

  • Picked for Nephrology (paper of the day, 19 November 2026): Compares targeted complement therapies for progressive glomerular disease

Abstract

BACKGROUND: C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are progressive kidney diseases driven by alternative complement pathway dysregulation. Although targeted complement inhibitors are promising, their comparative efficacy and safety remain uncertain. We evaluated these agents using Bayesian network meta-analysis. METHODS: We reviewed randomized controlled trials evaluating complement inhibitors in C3G and IC-MPGN (2015-2025). The primary outcome was relative change in proteinuria at 6-months. Secondary outcomes included change in estimated glomerular filtration rate (eGFR), C3G histologic index, and adverse events at 6-months. Treatment effects were estimated using Bayesian models and ranked using surface under the cumulative ranking curve (SUCRA). Sensitivity analyses included random-effects models and 52-week extension data. Certainty was assessed using GRADE-NMA. The protocol was registered in PROSPERO (CRD420251250384). RESULTS: Four trials, including 265 participants with trial-level mean ages 25-34 years (eligibility range, 12-80 years), evaluated pegcetacoplan, iptacopan, avacopan, and danicopan. Pegcetacoplan and iptacopan produced largest proteinuria reduction: pegcetacoplan -68.6% (95% credible interval [CrI], -83.2 to -54.0) and iptacopan -38.3% (95% CrI, -63.6 to -13.1) versus placebo (moderate certainty). In exploratory analyses, pegcetacoplan ranked highest (SUCRA 0.97), followed by iptacopan (0.66). Estimates for avacopan and danicopan were smaller, imprecise, and not statistically significant. Indirect comparisons were attenuated in sensitivity analyses, but hierarchy remained (low or very low certainty). Effects on eGFR were modest, without significant differences between active therapies. No therapy significantly improved C3G histologic index. Safety comparisons were limited by sparse events and short follow-up. CONCLUSIONS: Pegcetacoplan and iptacopan were associated with prompt proteinuria reduction versus placebo in C3G/IC-MPGN, while short-term kidney function improvements are expectedly modest. Although pegcetacoplan appeared more effective in the fixed-effect indirect analysis, between-treatment differences do not establish definitive superiority given their model-sensitivity, between trial differences and unavailability of long-term kidney outcomes. Longer-term follow-up, real-world comparative effectiveness data, and biomarker-driven studies are needed.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.